[go: up one dir, main page]

WO2005065664A8 - Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent - Google Patents

Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent

Info

Publication number
WO2005065664A8
WO2005065664A8 PCT/IN2005/000002 IN2005000002W WO2005065664A8 WO 2005065664 A8 WO2005065664 A8 WO 2005065664A8 IN 2005000002 W IN2005000002 W IN 2005000002W WO 2005065664 A8 WO2005065664 A8 WO 2005065664A8
Authority
WO
WIPO (PCT)
Prior art keywords
release form
agent
prokinetic agent
pharmaceutically acceptable
gastric acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2005/000002
Other languages
French (fr)
Other versions
WO2005065664A1 (en
Inventor
Rajesh Jain
Kour Chand Jindal
Sukhjeet Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Panacea Biotec Ltd
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP05709158A priority Critical patent/EP1729743A1/en
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Priority to YUP-2005/0796A priority patent/RS20050796A/en
Priority to NZ548780A priority patent/NZ548780A/en
Priority to CA002552627A priority patent/CA2552627A1/en
Priority to AP2006003703A priority patent/AP2006003703A0/en
Priority to BRPI0506704-9A priority patent/BRPI0506704A/en
Priority to EA200601286A priority patent/EA012261B1/en
Priority to AU2005204014A priority patent/AU2005204014B2/en
Publication of WO2005065664A1 publication Critical patent/WO2005065664A1/en
Publication of WO2005065664A8 publication Critical patent/WO2005065664A8/en
Priority to US11/482,186 priority patent/US20070160664A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Oral pharmaceutical compositions and process for preparation thereof are provided comprising at least one gastric acid suppressing agent, preferably a proton pump inhibitor or its pharmaceutically acceptable salts, esters, hydrates, derivatives or prodrugs, and one or more prokinetic agent or its pharmaceutically acceptable salts, esters, hydrates, derivatives or prodrugs, optionally with other pharmaceutically acceptable excipients, characterized in that the gastric acid suppressing agent is present in a delayed release form and the prokinetic agent is present in a bimodal release form such as an immediate release form to provide an initial loading dose, and a delayed release form to provide a dose with a lag time; with the provisio that the prokinetic agent is not formulated using a hydrophilic rate controlling polymer and is not present in a sustained release form. Method of treatment of gastro esophageal reflux disease, reflux esophagitis, peptic ulcer, gastric ulcer, and other gastric acid related disorders by administering to a patient such a pharmaceutical composition in need thereof is also provided.
PCT/IN2005/000002 2004-01-06 2005-01-05 Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent Ceased WO2005065664A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2005204014A AU2005204014B2 (en) 2004-01-06 2005-01-05 Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
YUP-2005/0796A RS20050796A (en) 2004-01-06 2005-01-05 Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
NZ548780A NZ548780A (en) 2004-01-06 2005-01-05 Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
CA002552627A CA2552627A1 (en) 2004-01-06 2005-01-05 Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
AP2006003703A AP2006003703A0 (en) 2004-01-06 2005-01-05 Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
EP05709158A EP1729743A1 (en) 2004-01-06 2005-01-05 Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
EA200601286A EA012261B1 (en) 2004-01-06 2005-01-05 Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
BRPI0506704-9A BRPI0506704A (en) 2004-01-06 2005-01-05 pharmaceutical compositions comprising proton pump inhibitor and prokinetic agent
US11/482,186 US20070160664A1 (en) 2004-01-06 2006-07-06 Pharmaceutical compositions comprising of proton pump inhibitor and prokinetic agent

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN25DE2004 2004-01-06
IN21DE2004 2004-01-06
IN21/DEL/2004 2004-01-06
IN25/DEL/2004 2004-01-06

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/482,186 Continuation-In-Part US20070160664A1 (en) 2004-01-06 2006-07-06 Pharmaceutical compositions comprising of proton pump inhibitor and prokinetic agent

Publications (2)

Publication Number Publication Date
WO2005065664A1 WO2005065664A1 (en) 2005-07-21
WO2005065664A8 true WO2005065664A8 (en) 2005-10-20

Family

ID=34751863

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2005/000002 Ceased WO2005065664A1 (en) 2004-01-06 2005-01-05 Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent

Country Status (11)

Country Link
US (1) US20070160664A1 (en)
EP (1) EP1729743A1 (en)
AP (1) AP2006003703A0 (en)
AU (1) AU2005204014B2 (en)
BR (1) BRPI0506704A (en)
CA (1) CA2552627A1 (en)
EA (1) EA012261B1 (en)
NZ (1) NZ548780A (en)
RS (1) RS20050796A (en)
WO (1) WO2005065664A1 (en)
ZA (1) ZA200606409B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
RU2467747C2 (en) * 2006-07-25 2012-11-27 Векта Лтд. Compositions and methods for gastric acid secretion inhibition with using small dicarboxylic acid derivatives in combination with ppi
ES2602789T3 (en) 2007-02-09 2017-02-22 Ocera Therapeutics, Inc. Connector intermediates for the synthesis of macrocyclic modulators of the ghrelin receptor
WO2010038241A2 (en) * 2008-09-30 2010-04-08 Panacea Biotec Limited Pharmaceutical compositions comprising of proton pump inhibitor, prokinetic agent and alginic acid
WO2011136750A1 (en) * 2010-04-26 2011-11-03 Mahmut Bilgic Pharmaceutical compositions inducing synergistic effect
EP2601936A4 (en) * 2010-08-03 2014-03-19 Eisai R&D Man Co Ltd Compressed composition
BRPI1103093A2 (en) * 2011-06-03 2013-07-02 Eurofarma Laboratarios Ltda oral pharmaceutical composition and use of the oral pharmaceutical composition
KR20130024644A (en) * 2011-08-31 2013-03-08 한국유나이티드제약 주식회사 Controlled-release oral drug preparations and it's manufacturing process containing itopride hydrochloride
JP2018518521A (en) 2015-06-26 2018-07-12 コリア ユナイテッド ファーマ． インコーポレーテッド Combination preparation of mosapride and rabeprazole
WO2024042540A1 (en) * 2022-08-24 2024-02-29 Alkem Laboratories Limited Mesdopetam compositions
WO2024224407A1 (en) * 2023-04-28 2024-10-31 Akums Drugs & Pharmaceuticals Limited Multi-layer pellet formulation and process of preparation thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08512322A (en) * 1993-07-06 1996-12-24 メルク エンド カンパニー インコーポレーテッド H-Lower 2 Antagonist-Gastrointestinal motility drug combination
SE9600072D0 (en) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
EP0951278A2 (en) * 1997-01-03 1999-10-27 ELAN CORPORATION, Plc Sustained release cisapride mini-tablet formulation
US6521255B2 (en) * 2000-01-13 2003-02-18 Osmotica Corp. Osmotic device containing ranitidine and a prokinetic agent
WO2004071374A2 (en) * 2003-02-11 2004-08-26 Torrent Pharmaceuticals Limited Once a day orally administered pharmaceutical compositions

Also Published As

Publication number Publication date
ZA200606409B (en) 2008-06-25
EA012261B1 (en) 2009-08-28
CA2552627A1 (en) 2005-07-21
RS20050796A (en) 2007-08-03
AU2005204014B2 (en) 2008-02-28
EA200601286A1 (en) 2007-02-27
NZ548780A (en) 2008-09-26
EP1729743A1 (en) 2006-12-13
WO2005065664A1 (en) 2005-07-21
AP2006003703A0 (en) 2006-08-31
BRPI0506704A (en) 2007-05-02
US20070160664A1 (en) 2007-07-12
AU2005204014A1 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
WO2007129195A3 (en) 4-pyrimidine-5-amino-pyrazole compounds
WO2005065664A8 (en) Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
WO2009076170A3 (en) Combinations of therapeutic agents for treating cancer
RU2013121788A (en) HIV REPLICATION INHIBITORS
WO2009017838A3 (en) Combinations of jak-2 inhibitors and other agents
NZ592615A (en) Method for treating or preventing thrombosis using 150 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
WO2008023258A8 (en) Piperidine derivatives
SI2760821T1 (en) Choline salt of an anti-inflammatory substituted cyclobutenedione compound
WO2007056219A3 (en) [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
WO2008009210A8 (en) Optical pure dihydropyrimidine compounds, their uses in the manufacture of a medicamnent for the treatment or the prevention of virosis diseases
MX2007004987A (en) New modified release tablet formulations for proton pump inhibitors.
WO2004071374A3 (en) Once a day orally administered pharmaceutical compositions
TN2009000452A1 (en) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
WO2010038241A3 (en) Pharmaceutical compositions comprising of proton pump inhibitor, prokinetic agent and alginic acid
WO2008002567A3 (en) Methods of treating conditions by sustained release administration of benzimidazole derivatives
CN102397277A (en) Pharmaceutical composition comprising esomeprazole
CA2648538A1 (en) Oral rapid release pharmaceutical formulation for pyridylmethylsulfinyl-benzimidazoles
AU2007278986B2 (en) Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI
NZ592613A (en) Method for treating or preventing thrombosis using >150 mg to 300 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
JP2011520868A (en) Compositions and methods for inhibiting gastric acid secretion
CA2595363A1 (en) Methods and materials with trans-clomiphene for the treatment of male infertility
JP2007504223A5 (en)
CA2633077A1 (en) Solid-state form of amg 706 and pharmaceutical compositions thereof
CN1744896B (en) Pharmaceutical composition combining tetoprazole and histamine H2 receptor antagonist
WO2005120518A3 (en) Use of atp analogues for treatment of cardiovascular diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-2005/0796

Country of ref document: YU

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 29/2005 UNDER (72, 75) REPLACE "SING, SUKHJEET" BY "SINGH, SUKHJEET"

WWE Wipo information: entry into national phase

Ref document number: 12006501304

Country of ref document: PH

Ref document number: 2552627

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/007779

Country of ref document: MX

Ref document number: 11482186

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005709158

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 548780

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: AP/P/2006/003703

Country of ref document: AP

WWE Wipo information: entry into national phase

Ref document number: 2006/06409

Country of ref document: ZA

Ref document number: 200606409

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2005204014

Country of ref document: AU

Ref document number: 200601286

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2005204014

Country of ref document: AU

Date of ref document: 20050105

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005204014

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005709158

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0506704

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 11482186

Country of ref document: US